Novel Therapeutics


The commonly used drug to treat Parkinson’s disease is Levodopa which has higher frequency to develop motor Fluctuations and results in L-dopa-induced dyskinesia (LID). Since the Characteristic key cause of Parkinson’s disease is reduced production level dopamine by neurons, research studies developed a molecule called LXR (Liver X Receptor) where it has got potential to reduce the loss of dopaminergic neurons. Researchers propose novel ideas to treat Parkinson’s disease to reduce the risk of causing side effects, frequency of dyskinesia, to treat cognitive disorders such as anxiety and depression.



 


  • Repetitive Transcranial Magnetic Stimulation
  • NMDA Receptor for Cognitive Dysfunction

Related Conference of Novel Therapeutics

December 04-05, 2023

5th International Conference on Neurologists

Prague, Czech Republic
December 11-12, 2023

5th World Brain Congress

Rome, Italy
February 01-02, 2024

33rd world congress on Neurology and Therapeutics

Dubai, UAE
February 08-09, 2024

4th Annual Dementia Congress

Paris, France
February 08-09, 2024

5th Global Summit on Brain Disorders and Therapeutics

Madrid, Spain
February 08-09, 2024

6th World Depression Congress

Paris, France
March 14-15, 2024

36th World Conference on Neurology

Paris, France
March 18-19, 2024

28th International Conference on Neurology & Neurophysiology

Zurich, Switzerland
April 11-12, 2024

36th World Congress on Neurorehabilitation

Amsterdam, Netherlands
April 11-12, 2024

38th European Neurology Congress

Amsterdam, Netherlands
April 11-12, 2024

36th World Neuroscience and Neurology Conferences

Amsterdam, Netherlands
May 30-31, 2024

2nd International conference on Neuro Surgery

Vienna, Austria
June 13-14, 2024

37th European Neurology Congress 2024

Rome, Italy
June 27-28, 2024

2nd International conference on Dementia

London, UK
August 13-14, 2024

14th Global Alzheimers Summit

Amsterdam, Netherlands

Novel Therapeutics Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in